New Podcast Alert!

BTOG does … Neo-adjuvant / peri-operative chemoimmunotherapy

@tnewsomdavis.bsky.social & Emma O'Dowd talk to Jason Adhikaree.

Subscribe via Apple App Store, Spotify or Amazon Music – just search BTOG or listen via the BTOG website.
www.btog.org/btog-podcasts/
#LCSM #lungcancer

The Lee lab is expanding! We are really interested in mechanisms of local and systemic immune tolerance particularly in liver metastases - X2 research technicians
💡 Creative fun environment
🌱 Opportunities to grow
🫂 Highly collaborative with clinical+basic research
📢 Please spread word!

It is a good Friday. Walking from Kelvingrove Art Gallery and Park along the River Kelvin to the Botanics in Glasgow's West End. Finish at Byres Road. Not done in a while and probably my favourite thing to do in the UK. Strong smell of wild garlic today.

3) KROCUS single arm phase 2 showing magnificent activity with fulverasib + cetuximab in 1st line nsclc, pdl1 agnostic. Very important and unexpected non IO option. It feels like egfr antibodies maybe offering something different to TKIs here. Again congrats+++ to all investigators #ELCC25

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

Outstanding RAS targeting presentations just passed at #ELCC25

I'm a little bit blown away...

Our excellent LCNEC project manager, Karen Shackcloth, presenting her poster yesterday at #BTOG2025

Her dedication to this role has been critical for our SIG efforts towards moving towards standardised diagnostic and management LCNEC pathways

Here is the wonderful Dr Ana Parreira presenting her poster on KRASm radiotherapy outcomes at #BTOG2025

Ana is a Portuguese medical oncologist bridging the clin med oncology divide with unrelenting diplomacy and discipline!

@mcrcnews.bsky.social

En route to #BTOG25? The team are ready! Looking forward to seeing you there. Do say “hello” when you catch me! It will be an awesome meeting! @btog.bsky.social

Lovely night with our @uom-dcs.bsky.social Medical Oncology clinical academic trainees (ACFs/ACLs) who are thankfully growing in number. With @drcolinlindsay.bsky.social. Great to see everyone! @mcrcnews.bsky.social

Excellent summary of what was a superb meeting on precision medicine for KRAS and the MAP kinase pathway.

magazine.eacr.org/highlights-f...

Thanks again +++ @helloeacr.bsky.social and @boehringerglobal.bsky.social for the invitation.

@mcrcnews.bsky.social
@cruk-mi.bsky.social

Amazing speakers, location, hospitality. Make sure you come if interested in RAS precision medicine!

Other thing at the end of 2024 - I caught up with my friend and tireless advocate for KRAS research, Terri Conneran of KRAS Kickers, for a webinar on RAS translation.
www.youtube.com/channel/UCUI...

@official-uom.bsky.social @cancerresearchuk.org @cruk-mi.bsky.social @kraskickers.bsky.social

We had a fantastic end to 2024 in the Manchester RAS lab www.mcrc.manchester.ac.uk/research/dis...

Our 1st PhD student passed his viva...George Morrissey is now beginning med onc training and is destined for great things.
@official-uom.bsky.social @cruk-mi.bsky.social